ClinicalTrials.gg
CompletedNCT00151502Updated Feb 18, 2021

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

A Phase 3 interventional study of Atorvastatin in Alzheimer's Disease, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 99 sites in 10 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
154th of 1,611
600 · median 73
Started
2002
with 14 others
Phase 3
188 of 1,942
19 open now
Registered
107th of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 154th largest by enrollment of the 1,611 interventional ones that give a count, is one of 15 that started in 2002, is one of 188 in phase 3, and was the 107th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and DSM IV criteria.
  • Subject's Mini-Mental Status Examination Score () must be in the range of 13 - 25 (inclusive) at Screening.

Exclusion criteria

Exclusion Criteria:

  • Subjects with dementia due to causes other than Alzheimer's disease.
  • Any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet the objectives of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. If the results of this study demonstrate efficacy and lead to the approval by the FDA of atorvastatin for use in humans for the treatment of Alzheimer's disease, this would be available as an additional treatment option for patients.

Secondary outcomes

  1. If the results of this study demonstrate efficacy and lead to the approval by the Food and Drug Administration of atorvastatin for use in humans, subject activities of daily living are being assessed.

07

Study locations

99 sites
  • Pfizer Investigational Site
    Sun City, Arizona 85351, United States
  • Pfizer Investigational Site
    Fresno, California 93720, United States
  • Pfizer Investigational Site
    Laguna Hills, California 92653, United States
  • Pfizer Investigational Site
    San Francisco, California 94109, United States
  • Pfizer Investigational Site
    Fort Lauderdale, Florida 33321, United States
  • Pfizer Investigational Site
    Fort Myers, Florida 33912, United States
  • Pfizer Investigational Site
    Miami Beach, Florida 33154, United States
  • Pfizer Investigational Site
    Pompano Beach, Florida 33064, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33702, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33407, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46805, United States
  • Pfizer Investigational Site
    Paducah, Kentucky 42003, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    South Dartmouth, Massachusetts 02747, United States
  • Pfizer Investigational Site
    West Yarmouth, Massachusetts 02673, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts 01655, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49048-1640, United States
  • Pfizer Investigational Site
    Jamesburg, New Jersey 08831, United States
  • Pfizer Investigational Site
    Princeton, New Jersey 08540, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Pfizer Investigational Site
    Albany, New York 12208, United States
  • Pfizer Investigational Site
    Rochester, New York 14620, United States
  • Pfizer Investigational Site
    Troy, New York 12180, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Pfizer Investigational Site
    Allentown, Pennsylvania 18013, United States
  • Pfizer Investigational Site
    Allentown, Pennsylvania 18103, United States
  • Pfizer Investigational Site
    Jenkintown, Pennsylvania 19046, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15205, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    East Providence, Rhode Island 02914, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02906, United States
  • Pfizer Investigational Site
    Madison, Tennessee 37115, United States
  • Pfizer Investigational Site
    Austin, Texas 78756-3433, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Wichita Falls, Texas 76309, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Seattle, Washington 98108, United States
  • Pfizer Investigational Site
    Madison, Wisconsin 53705, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • Pfizer Investigational Site
    East Gosford, New South Wales 2250, Australia
  • Pfizer Investigational Site
    Randwick, New South Wales 2031, Australia
  • Pfizer Investigational Site
    Daw Park, South Australia 5041, Australia
  • Pfizer Investigational Site
    Woodville South, South Australia 5011, Australia
  • Pfizer Investigational Site
    Ballarat, Victoria 3350, Australia
  • Pfizer Investigational Site
    WEST Heidelberg, Victoria 3081, Australia
  • Pfizer Investigational Site
    Nedlands, Western Australia 6009, Australia
  • Pfizer Investigational Site
    Wein, A-1130, Austria
  • Pfizer Investigational Site
    Wien, A-1030, Austria
  • Pfizer Investigational Site
    Wien, A-1220, Austria
  • Pfizer Investigational Site
    Calgary, Alberta T2N 4N1, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6T 2B5, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 2E1, Canada
  • Pfizer Investigational Site
    London, Ontario N6C 5J1, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • Pfizer Investigational Site
    Verdun, Quebec H4H-1R3, Canada
  • Pfizer Investigational Site
    Quebec, G1J 1Z4, Canada
  • Pfizer Investigational Site
    Aarhus, 8000, Denmark
  • Pfizer Investigational Site
    Copenhagen, 2100, Denmark
  • Pfizer Investigational Site
    Hillerod, 3400, Denmark
  • Pfizer Investigational Site
    Rudkobing, 5900, Denmark
  • Pfizer Investigational Site
    Svendborg, 5700, Denmark
  • Pfizer Investigational Site
    Bad Honnef, 53604, Germany
  • Pfizer Investigational Site
    Berlin, 13347, Germany
  • Pfizer Investigational Site
    Bochum, D-44892, Germany
  • Pfizer Investigational Site
    Bonn, 53105, Germany
  • Pfizer Investigational Site
    Goettingen, 37073, Germany
  • Pfizer Investigational Site
    Hannover, 30559, Germany
  • Pfizer Investigational Site
    Muenchen, 80336, Germany
  • Pfizer Investigational Site
    Muenchen, 81675, Germany
  • Pfizer Investigational Site
    Tuebingen, 72076, Germany
  • Pfizer Investigational Site
    Rosebank, Gauteng 2196, South Africa
  • Pfizer Investigational Site
    Willows, Gauteng 0041, South Africa
  • Pfizer Investigational Site
    Pinetown, Kwazulu Natal 3600, South Africa
  • Pfizer Investigational Site
    Belleville, 7530, South Africa
  • Pfizer Investigational Site
    Westville, 3630, South Africa
  • Pfizer Investigational Site
    Terrassa, Barcelona 08221, Spain
  • Pfizer Investigational Site
    Barcelona, 08003, Spain
  • Pfizer Investigational Site
    Barcelona, 08014, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Madrid, 28046, Spain
  • Pfizer Investigational Site
    Madrid, 28050, Spain
  • Pfizer Investigational Site
    Linkoeping, SE-58185, Sweden
  • Pfizer Investigational Site
    Malmoe, SE-20502, Sweden
  • Pfizer Investigational Site
    Moelndal, SE-43180, Sweden
  • Pfizer Investigational Site
    Stockholm, 18146, Sweden
  • Pfizer Investigational Site
    Uddevalla, SE-45180, Sweden
  • Pfizer Investigational Site
    Bradford, England BD5 OBS, United Kingdom
  • Pfizer Investigational Site
    Stirling, Stirlingshire FK8 1PH, United Kingdom
  • Pfizer Investigational Site
    Swindon, Wiltshire SN1 4JU, United Kingdom
  • Pfizer Investigational Site
    Bath, BA2 5RP, United Kingdom
  • Pfizer Investigational Site
    Belfast, BT9 7BL, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G20 0XA, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G51 4TF, United Kingdom
  • Pfizer Investigational Site
    Penarth, CF642XX, United Kingdom
  • Pfizer Investigational Site
    Southhampton, SO30 3JB, United Kingdom
  • Pfizer Investigational Site
    Stirling, FK8 1RW, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 9, 2005
Start
Nov 2002
CompletionActual
Jul 2007
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00151502
Responsible party
Sponsor
First posted
Sep 9, 2005
Start date
Nov 2002
Completion
Jul 2007
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion